British Bio-technology Limited

British Biotech Pharmaceuticals Limited

Alan H Davidson

Jonathan P Dickens

Michael John Crimmin

Colin Campion

Mark Whittaker

Zoe Marie Spavold

Christopher Norman Lewis

Christopher D Floyd

Richard S Todd

Stephen Arthur Bowles

Nigel Mark Allanson

Alan H Drummond

Compounds of general Formula I: ##STR1## are presented which have collagenase inhibition activity and are useful in the management of disease involving tissue degradation and the promotion of wound healing. Representative diseases involving include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption disease and tumor invasion.

Compounds

Disaccharide ligands for selectins

Compounds of general formula I: ##STR1## wherein: R.sup.1 represents a C.sub.1 -C.sub.6 alkyl, phenyl, thiophenyl, substituted phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, heterocyclyl, (C.sub.1 -C.sub.6)alkylcarbonyl phenacyl or substituted phenacyl group; or, when n=O, R.sup.1 represents SR.sup.x, wherein R.sup.x represents a group: ##STR2## R.sup.2 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl(C.sub.1 -C.sub.6)alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl or cycloalkenyl(C.sub.1 -C.sub.6)alkyl group;

Hydroxamic acid based collagenase inhibitors

Compounds of general formula I: ##STR1## wherein: A represents the group --NH.sub.2, a substituted acyclic amine or a heterocyclic base; have collagenase inhibition activity and are useful in the management of disease involving tissue degradation and/or the promotion of wound healing. Diseases involving tissue degradation include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption diseases and tumour invasion.

Lactol PAF antagonists

Compounds of general formula I: ##STR1## wherein: each of R.sup.1 -R.sup.8, k, and V represent disclosed functional groups that have been chosen such that all disclosed variations of compound I and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.

Benzimidazole derivatives

Hydroxamino acid based collagenase inhibitors

6-(hydronaphtyl-1-ethyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones

Hydroxamic acid collagenase inhibotors

Compounds of general formula I; ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are variables. These compounds are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.

Spirocyclic PAF antagonists

Compounds of either of general formulae I and II: ##STR1## wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6, a, b, c, and d are variables. These compounds are useful in the treatment of hypercholesterolaemia in general and arteriosclerosis, familial hypercholesterolaemia or hyperlipidaemia in particular.

Decaline based HMC-COA reductase inhibitors with two C-6 substituents

Growing community of inventors

Oxon, United Kingdom

Alan H Davidson